Distalmotion has raised $150 million in Series G financing to speed U.S. adoption of its Dexter robotic surgery platform, with a focus on ambulatory surgery centers.

The financing round was led by Revival Healthcare Capital and included participation from existing investors. Distalmotion said the new capital will support both commercial expansion and continued development of the Dexter system, which is designed for soft tissue surgery and recently received FDA clearance for use in benign gynecologic procedures.

The company sees ambulatory surgery centers (ASCs) as a key growth market. ASCs continue to gain ground in surgical care due to their lower cost structure and alignment with the broader push toward outpatient procedures. Distalmotion said Dexter’s compact design and flexible setup make it well suited for these settings.
In a statement, CEO Greg Roche said, “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of U.S. market acceleration, ASCs represent a tremendous opportunity for Dexter.”

Dexter has been used in clinical settings in both Europe and the U.S., with nearly 3,000 procedures completed, according to the company.

The Switzerland-based medtech firm also named Chas McKhann as executive chairman of its board. He previously held CEO roles at Apollo Endosurgery and Silk Road Medical, where he led both companies through commercial growth and eventual exits.

“I am thrilled to join the Distalmotion team,” McKhann said. “With the recent FDA clearance in gynecology and release of Dexter product enhancements, the company is poised to accelerate adoption in the U.S. and globally at this pivotal stage in its growth trajectory.”

Dexter is currently approved in the U.S. for inguinal hernia repair, cholecystectomy, and benign hysterectomy procedures in adults.

U.S. Healthcare Homepage